Vor Biopharma Inc.
NASDAQ:VORBiotechnology
-$0.34 today
- Market cap
- $966.13M
- Beta
- 1.73
- P/E (TTM)
- -0.0
- EPS (TTM)
- -$2,053.13
Volume 0.79M
Average 1.07M
VOR Weighted Avg Shares (Diluted)
Average shares outstanding including dilutive securities, used to calculate diluted EPS.
Vor Biopharma Inc.NASDAQ: VOR
Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026
Weighted avg shares (diluted) dips below year-ago levels
Q1 FY2026 weighted avg shares (diluted) of 430.12K shares fell 93.1% year over year, behind the +40.8% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it fell 95.6% from the prior quarter. Over 3 fiscal years it compounded at +70.9% a year.
Context
- Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -93.1% toward the trailing-twelve-month pace of +40.8%.
Sources:Income StatementText generated from reported figures; not investment advice.
Weighted Avg Shares (Diluted) history
Shares · from the income statement
- Latest · FY2025
- 9.87M USD
- Year-over-year change
- +187.4%
- 4-year CAGR
- +51.8%
| Period | Period end | Weighted Avg Shares (Diluted) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 9.87M | +187.4% |
| FY2024 | 2024-12-31 | 3.44M | +2.3% |
| FY2023 | 2023-12-31 | 3.36M | +69.9% |
| FY2022 | 2022-12-31 | 1.98M | +6.4% |
| FY2021 | 2021-12-31 | 1.86M | — |
Weighted Avg Shares (Diluted) vs competitors
How VOR compares with its peers on the latest reported figures
- VOR's LTM Mar 2026 weighted avg shares (diluted) of 5.81M shares is the lowest of the 10 companies compared; the peer median is 110.2M shares.
- Its year-over-year change of +40.8% is the highest of 10, against a peer median of +8.4%.
- Over three fiscal years its annual growth of +70.9% compares with a peer median of +12.1%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | 266.14M | +0.0% | +41.0% | |
| LTM Mar 2026 | 257.25M | +9.0% | +10.4% | |
| LTM Mar 2026 | 119.09M | +1.0% | +7.1% | |
| LTM Mar 2026 | 111.46M | +12.7% | +17.7% | |
| LTM Mar 2026 | 110.2M | +9.3% | +12.1% | |
| LTM Sep 2026 | 94.81M | +8.4% | +5.0% | |
| LTM Mar 2026 | 90.28M | +9.3% | +8.9% | |
| LTM Mar 2026 | 86.45M | +4.3% | +14.4% | |
| LTM Mar 2026 | 74.08M | +0.6% | +19.3% | |
| LTM Mar 2026 | 5.81M | +40.8% | +70.9% | |
| Peer median (excluding VOR) | 110.2M | +8.4% | +12.1% | |
Competitors are the stored peer set for VOR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 8.96M | 3.49M | 0 | 0 |
| Gross Profit | 0 | (8.96M) | (3.49M) | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 47.53M | 64.55M | 94.32M | 93.31M | 321.53M |
| Selling, General & Admin | 21.49M | 19.91M | 31.72M | 27.88M | 50.11M |
| Operating Expenses | 69.02M | 84.46M | 122.54M | 121.19M | 371.64M |
| Depreciation & Amortization | 1.43M | 8.96M | 3.49M | 3.53M | 2.89M |
| EBITDA | (67.47M) | (83.13M) | (114.37M) | (113.39M) | (693.09M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (69.02M) | (93.42M) | (126.04M) | (121.19M) | (371.64M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 119K | 1.32M | 8.17M | 4.27M | 5.87M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 119K | 1.32M | 8.17M | 4.27M | (324.34M) |
| Income Before Tax | (68.9M) | (92.09M) | (117.86M) | (116.91M) | (695.98M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (68.9M) | (92.09M) | (117.86M) | (116.91M) | (695.98M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (37.80) | (46.60) | (35.00) | (34.00) | (70.50) |
| EPS (Diluted) | (37.80) | (46.60) | (35.00) | (34.00) | (70.50) |
| Weighted Avg Shares | 1.86M | 1.98M | 3.36M | 3.44M | 9.87M |
| Weighted Avg Shares (Diluted) | 1.86M | 1.98M | 3.36M | 3.44M | 9.87M |
Vor Biopharma Inc.
NASDAQ:VOR
Intrinsic Alpha fair value
Locked
Current Price
$17.83
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.